Barclays’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$6.13M Sell
231,200
-214,495
-48% -$5.68M ﹤0.01% 1468
2025
Q1
$10.8M Buy
445,695
+353,139
+382% +$8.53M ﹤0.01% 975
2024
Q4
$3.72M Sell
92,556
-10,575
-10% -$425K ﹤0.01% 1806
2024
Q3
$6.53M Buy
103,131
+13,896
+16% +$880K ﹤0.01% 1317
2024
Q2
$4.73M Sell
89,235
-59,368
-40% -$3.15M ﹤0.01% 1209
2024
Q1
$12.2M Sell
148,603
-391,110
-72% -$32.1M ﹤0.01% 920
2023
Q4
$10M Buy
539,713
+17,791
+3% +$331K ﹤0.01% 1054
2023
Q3
$5.78M Buy
521,922
+332,913
+176% +$3.69M ﹤0.01% 1071
2023
Q2
$3.07M Buy
189,009
+8,130
+4% +$132K ﹤0.01% 1484
2023
Q1
$3.01M Buy
180,879
+142,664
+373% +$2.38M ﹤0.01% 1387
2022
Q4
$359K Buy
38,215
+34,180
+847% +$321K ﹤0.01% 2786
2022
Q3
$11K Buy
4,035
+4,034
+403,400% +$11K ﹤0.01% 4152
2022
Q2
$0 Sell
1
-11,429
-100% ﹤0.01% 4930
2022
Q1
$35K Sell
11,430
-71,602
-86% -$219K ﹤0.01% 4136
2021
Q4
$382K Buy
83,032
+54,515
+191% +$251K ﹤0.01% 2628
2021
Q3
$180K Buy
28,517
+19,003
+200% +$120K ﹤0.01% 3025
2021
Q2
$57K Sell
9,514
-72,283
-88% -$433K ﹤0.01% 3348
2021
Q1
$517K Buy
81,797
+27,952
+52% +$177K ﹤0.01% 2641
2020
Q4
$303K Sell
53,845
-20,145
-27% -$113K ﹤0.01% 2539
2020
Q3
$430K Sell
73,990
-43,951
-37% -$255K ﹤0.01% 2382
2020
Q2
$850K Buy
117,941
+41,035
+53% +$296K ﹤0.01% 2019
2020
Q1
$359K Sell
76,906
-2,287
-3% -$10.7K ﹤0.01% 2277
2019
Q4
$635K Buy
79,193
+45,173
+133% +$362K ﹤0.01% 2565
2019
Q3
$234K Sell
34,020
-28,509
-46% -$196K ﹤0.01% 2995
2019
Q2
$519K Buy
62,529
+45,264
+262% +$376K ﹤0.01% 2698
2019
Q1
$172K Buy
17,265
+5,618
+48% +$56K ﹤0.01% 3097
2018
Q4
$89K Sell
11,647
-137,082
-92% -$1.05M ﹤0.01% 3011
2018
Q3
$2.59M Sell
148,729
-90,224
-38% -$1.57M ﹤0.01% 1565
2018
Q2
$2.27M Buy
238,953
+224,280
+1,529% +$2.13M ﹤0.01% 1366
2018
Q1
$64K Buy
14,673
+12,988
+771% +$56.7K ﹤0.01% 3378
2017
Q4
$7K Buy
+1,685
New +$7K ﹤0.01% 3865